Well, I get it
But odds are very high now, we likely have 30-60 events differential and we only need 30 ( crude number, crude way of looking at it )
I think we have at least 14 more than 30, or 44.
that's a lot of difference between two groups of appx. 400 each.
If 20 people have dropped out of the study, half or so would be expected to have been "an event", or about 10. 44-10 = 34, still more than enough.
And even if we miss by a few, we're still, I think, beating ipilimumab and nivolumab in a total random population without pre-selection for certain marker(s).
The more time goes on the more we're likely to be seeing "truth" from the Phase II study, which means the differential is at least 66 given roughly the same %responding to injection. I think it will be a bit higher than 42% at 50% or more in a larger study.
If we make it past this study, then we can try combinations which are showing great promise in others. If we improve that 66 to 100, then there is a very strong possibility that 1/4th more of people with H&N cancer will not die from it in the near future.
That's huge.
So there is a lot to shake out in the "final analysis".
News 
Market Data 
Discover 
